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by three blinded readers. Findings at
CT and MRI were compared with
those at intraoperative US, which
were used as term of reference. In-
traoperative US detected 128 metas-
tases. In a lesion-by-lesion analysis,
the overall detection rate was 71%
(91 of 128) for spiral CT, 72% (92 of
128) for unenhanced MRI, and 90%
(115 of 128) for MnDPDP-enhanced
MRI. MnDPDP-enhanced MRI was
more sensitive than either unen-
hanced MRI (p<0.0001) or spiral CT
(p=0.0007). In a patient-by-patient
analysis, agreement with gold stan-
dard was higher for MnDPDP-en-
hanced MRI (33 of 44 cases) than
for spiral CT (22 of 44 cases,
p=0.0023) and unenhanced MRI (21
of 44 cases, p=0.0013). MnDPDP-
enhanced MRI is superior to unen-
hanced MRI and spiral CT in the 
detection of hepatic colorectal me-
tastases.
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Introduction
Metastatic disease in the liver usually indicates advanced
disease and a poor prognosis. In patients with hepatic
metastases from primary malignancies developed in the
gastrointestinal tract, particularly colorectal adenocarci-
noma, a substantial improvement in long-term survival
can be achieved with surgical removal or percutaneous
ablation of the metastatic burden [1, 2, 3, 4, 5]. A 5-year
survival rate of approximately 20–40% and a 5-year dis-
ease-free survival rate of approximately 20–25%, in fact,
can be expected in successfully treated patients [6, 7].
The success of surgery and tumor ablation therapies
depends on the knowledge of the exact number and loca-
tion of metastatic lesions [7]. Several CT and MR exami-
nation protocols have been used for preoperative detec-
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Abstract The aim of this study was
to compare unenhanced MRI,
MnDPDP-enhanced MRI, and spiral
CT in the detection of hepatic colo-
rectal metastases. Forty-four patients
with hepatic colorectal metastases
were examined with unenhanced and
MnDPDP-enhanced MRI and with
unenhanced and contrast-enhanced
spiral CT. The MR examination pro-
tocol included baseline T1-weighted
spin-echo (SE), T1-weighted gradi-
ent-recalled-echo (GRE), and T2-
weighted fast-SE sequences; and 
T1-weighted SE and T1-weighted
GRE sequences obtained 30–60 min
after administration of 0.5 µmol/kg
(0.5 ml/kg) mangafodipir trisodium
(MnDPDP). Images were interpreted
provided by findings at visual inspection of the liver surface and
intraoperative US. Lesions which were identified for the first time
at intraoperative US were resected whenever possible together
with the known tumor. In resected cases, findings at intraoperative
US were then matched with those at pathology examination of the
surgical specimen. If lesions identified at intraoperative US were
in locations that made hepatic resection inappropriate, they were
treated intraoperatively by US-guided radio-frequency thermal ab-
lation.
Images were interpreted blindly and prospectively by three
readers who were asked to reach a consensus. For the primary end
point of the study, the readers evaluated three sets of images for
each patient. The first set contained baseline T1-weighted SE, 
T1-weighted GRE, and T2-weighted FSE sequences; the second
set contained baseline T1-weighted SE, T1-weighted GRE, and
T2-weighted FSE sequences plus MnDPDP-enhanced T1-weight-
ed SE and T1-weighted GRE sequences; and the third set con-
tained unenhanced plus contrast-enhanced spiral CT images. For
the secondary end points of the study, each MR pulse sequence
was then evaluated separately. Lesion conspicuity and quality of
lesion delineation were graded as: absent; poor; moderate; or ex-
cellent. The level of confidence in the diagnosis was graded as:
not very confident; moderately confident; very confident; or ex-
tremely confident.
The statistical analysis of the results was performed using the
McNemar test and the Wilcoxon t test for paired data. A p value
less than 0.05 was considered statistically significant.
Results
Findings at intraoperative US showed 128 metastatic le-
sions, ranging 0.2–12.0 cm in diameter. Forty seven of
128 lesions were smaller than or equal to 1 cm in diame-
ter, 31 ranged 1.1–2 cm, and 45 were larger than 2 cm.
Pathologic confirmation of metastasis was achieved in
89 of 128 lesions that were surgically resected. The re-
maining 39 of 128 lesions were submitted to intra-opera-
tive radio-frequency thermal ablation.
In the lesion-by-lesion analysis, the overall detection
rate was 71% (91 of 128 lesions) for spiral CT, 72% (92
of 128) for unenhanced MRI, and 90% (115 of 128) for
MnDPDP-enhanced MRI. MnDPDP-enhanced MRI was
more sensitive than either unenhanced MRI (p<0.0001)
or spiral CT (p=0.0007; Figs. 1, 2, 3). In lesions ≤1 cm
in diameter, the difference in sensitivity among spiral CT
(38%), unenhanced MRI (51%), and MnDPDP-enhanced
MRI (83%) was even more manifest (Table 1). All le-
sions undetected by MnDPDP-enhanced MRI and dis-
covered at the time of surgery by intraoperative US did
not exceed 1 cm in diameter.
In the patient-by-patient analysis, agreement with
gold standard in assessing the hepatic metastatic tumor
burden was higher for MnDPDP-enhanced MRI (33 of
44 cases) than for spiral CT (22 of 44 cases, p=0.0023)
and unenhanced MRI (21 of 44 cases, p=0.0013). Under-
stimation of lesions (false negatives) were observed in
19 patients at spiral CT, in 21 patients at unenhanced
MRI, and in 9 patients at MnDPDP-enhanced MRI.
Overestimation of lesions (false positives) were observed
in 3 patients at spiral CT, in 2 patients at unenhanced
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tion of liver metastases [8, 9, 10]. In MRI, efforts aimed
at enhancing lesion detectability have been especially fo-
cused on the development of tissue-specific contrast
agents, including reticulo-endothelial-system-targeted
agents and hepatobiliary agents [11, 12].
Mangafodipir trisodium is a paramagnetic hepatobili-
ary MR contrast agent. Following intravenous adminis-
tration, Mn is taken up by the hepatocytes. This leads, as
a consequence of T1-shortening, to an increased signal
intensity of normal hepatic parenchyma, thus enhancing
contrast between liver and focal lesions Several studies
have investigated the usefulness of MRI after adminis-
tration of MnDPDP [13, 14, 15, 16, 17, 18, 19]. There
appears to be consensus that MnDPDP-enhanced MRI
improves lesion conspicuity and increases lesion detec-
tion rate. The role of MnDPDP-enhanced MRI with re-
spect to spiral CT in the preoperative assessment of pa-
tients with liver metastases, however, has not been fully
defined. The purpose of this study was to compare
MnDPDP-enhanced MRI with spiral CT for the detec-
tion of hepatic colorectal metastases in a series of pa-
tients who were candidates for surgical resection or in-
traoperative radio-frequency thermal ablation.
Materials and methods
The study was designed as a prospective, multi-institutional trial.
The primary end point of the study was to compare the sensitivity
of unenhanced and Mn-DPDP-enhanced MRI with that of spiral
CT in the detection of hepatic colorectal metastases in lesion-
by-lesion and patient-by-patient analyses. Secondary end points
included the assessment of (a) lesion conspicuity, (b) quality of le-
sion delineation, and (c) confidence in diagnosis in each unen-
hanced or enhanced MR pulse sequence and in spiral CT images.
Inclusion criteria were: (a) adult patient with hepatic colorectal
cancer metastasis; (b) patient scheduled for partial hepatectomy or
intra-operative radio-frequency thermal ablation; and (c) signed
written informed consent. Exclusion criteria were: (a) pregnant or
lactating woman; (b) inclusion in other investigational study in the
7 days prior to the enrollment; (c) severe obstructive biliary dis-
ease or renal insufficiency; (d) severe hepatic dysfunction (Child
class C); and (e) general contraindication to MRI.
A series of 44 consecutive adult patients with hepatic colorec-
tal metastases, referred to the participating centers for pre-opera-
tive imaging assessment, were included in the study. Twenty-two
patients were enrolled in Pisa, 7 in Verona, 6 in Brescia, 5 in 
Genoa, 2 in Ancona, and 2 in Turin. All patients underwent unen-
hanced and MnDPDP-enhanced MRI at 0.5 T (n=8), 1.0 T (n=6),
or 1.5 T (n=30) as well as unenhanced and contrast-enhanced spi-
ral CT.
Magnetic resonance examination protocol included baseline
T1-weighted SE and GRE sequences and T2-weighted fast-spin-
echo (FSE) sequences. The T1-weighted SE and GRE sequences
were then repeated 30–60 min following IV infusion of
0.5 µmol/kg (0.5 ml/kg) MnDPDP (Teslascan, Amersham Health,
Oslo, Norway) at the rate of 2.5 ml/min. In each center, the routine
parameters used for liver MR studies were used. Also, unenhanced
and contrast-enhanced CT studies were optimized for liver metas-
tasis detection according to the standard examination protocol
adopted in each center.
All patients underwent either partial hepatectomy or intra-
operative radio-frequency thermal ablation. Gold standard was
16
Fig. 1  a Unenhanced T1-weighted MR image shows solitary me-
tastasis in segment VII (arrow). b After injection of mangafodipir
trisodium (MnDPDP), lesion conspicuity is increased, and a sec-
ond metastasis, undetected by baseline MR examination, is ob-
served in the anterior subcapsular aspect of segment III (arrow)
Fig. 2  a Contrast-enhanced spiral CT fails to show any lesion in
the level shown. b MnDPDP-enhanced T1-weighted gradient-re-
called-echo (GRE) MR image shows tiny metastasis <1 cm in
greatest dimension (arrow)
Table 1 Comparison among
unenhanced MRI, MnDPDP-
enhanced MRI, and spiral CT
in the detection of hepatic colo-
rectal metastases in a lesion-
by-lesion analysis according to
lesion size
Imaging study No. of lesions detected/studied
≤1 cm 1.1–2 cm >2 cm Overall
Spiral CT 18/47 (38) 28/31 (90) 45/45 (100) 91/128 (71)
Unenhanced MRI 24/47 (51) 24/31 (77) 44/45 (98) 92/128 (72)
Enhanced MRIa 39/47 (83) 31/31 (100) 45/45 (100) 115/128 (90)b
Numbers in parentheses are percentages
a Enhanced MRI includes baseline and MnDPDP-enhanced sequences
b Enhanced MRI was significantly more sensitive than either unenhanced MRI (p<0.0001) or spiral
CT (p=0.0007). The Wilcoxon t test for paired data was used for statistical analysis
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MRI, and in 2 patients at MnDPDP-enhanced MRI 
(Table 2). Lesions overestimated as metastases were di-
agnosed as hemangioma (n=1) or cyst (n=2) intraopera-
tively.
Lesion conspicuity, quality of lesion delineation, and
confidence in diagnosis were all significantly higher for
post-contrast T1-weighted GRE images than any other
pre-contrast or post-contrast MR images or for spiral CT
images (Tables 3, 4, 5).
Discussion
Many studies have compared different imaging modalities
or different methods or examination protocols within the
same modality in attempts to optimize detection of colo-
rectal liver metastases, particularly in patients who are
candidates for partial hepatectomy. Until recently, the gen-
eral opinion was that CT during arterial portography was
the best preoperative method for the detection of hepatic
metastases, with a sensitivity ranging between 89 and
94% in series in which surgical confirmation was obtained
[20, 21, 22, 23]. Computed tomographic arterial portogra-
phy, however, is an invasive procedure that requires angi-
ography. Moreover, it has a high false-positive rate, due to
the presence of benign liver tumors—such as hemangio-
mas, nontumorous portal vein perfusion defects, and small
cysts, all of which may simulate tumor [22].
With improvements in hardware and software, MRI
has in recent years assumed an important role in the
Fig. 3  a Contrast-enhanced
spiral CT does not show any
focal abnormality. b MnDPDP-
enhanced T1-weighted GRE
MR image shows a 1-cm me-
tastasis in segment V (arrow).
Right adrenal adenoma is also
detected
Table 2 Comparison among unenhanced MRI, MnDPDP-enhanced
MRI, and spiral CT in the assessment of the hepatic metastatic tu-
mor burden in a patient-by-patient analysis
Imaging study Comparison with intraoperative US findings
Underestimation Agreement Overestimation 
of lesions of lesions
Spiral CT 19/44 (43) 22/44 (50) 3/44 (7)
Unenhanced MRI 20/44 (45) 22/44 (50) 2/44 (5)
Enhanced MRIa 9/44 (20) 33/44 (75)b 2/44 (5)
Numbers are numbers of patients. Numbers in parentheses are per-
centages
a Enhanced MRI includes baseline and MnDPDP-enhanced se-
quences
b Enhanced MRI was significantly more accurate than either unen-
hanced MRI (p=0.0013) or spiral CT (p=0.0023). The McNemar
test was used for statistical analysis
Table 3 Lesion conspicuity in unenhanced MR images, MnDPDP-enhanced MR images, and spiral CT images. SE spin echo, GRE gra-
dient-recalled echo, FSE fast spin echo
Absent Poor Moderate Excellent Not assessed
Spiral CT – 6 (6.6) 39 (42.9) 46 (50.6) –
Unenhanced T1-weighted SE 1 (1.3) 21 (28.0) 42 (56.0) 11 (14.7) –
Unenhanced T1-weighted GRE – 13 (14.1) 51 (55.4) 28 (30.4) –
Unenhanced T2-weighted FSE – 15 (17.2) 43 (49.4) 28 (32.2) 1 (1.2)
MnDPDP-enhanced T1-weighted SE – 13 (14.6) 38 (42.7) 38 (42.7) –
MnDPDP-enhanced T1-weighted GRE – – 19 (16.5) 96 (83.5) –
Numbers in parentheses are percentages
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evaluation of the liver for focal diseases. The sensitivity
of unenhanced MRI, however, is considered to be equal
or at best only marginally higher than that of contrast-
enhanced CT [11]. Moreover, MRI enhanced with extra-
cellular contrast agents, i.e., gadolinium chelates,
showed no improvement over unenhanced MRI in de-
tectability of liver metastases, particularly when blinded
readers from different institutions were used [24, 25, 26].
In one study, the number of false-positive and false-neg-
ative diagnoses of individual lesions were higher with
dynamic gadolinium-enhanced MR images than with un-
enhanced images [26].
With the advent of tissue-specific MR contrast media,
investigation has been focused on assessing the value of
MRI after administration of reticulo-endothelial-system-
targeted agents, such as ferumoxides, or hepatobiliary
agents for the detection of focal liver lesions. Previous
studies have shown the usefulness of ferumoxides-en-
hanced MRI for increasing tumor-to-liver contrast and
improving lesion conspicuity on T2-weighted images
[27, 28, 29]. In one series, ferumoxides-enhanced MRI
was at least as accurate as CT arterial portography for
the detection of hepatic metastases [30]. In two compari-
sons of MR imaging findings with the results of intraop-
erative US and pathologic examination, the sensitivity of
ferumoxides-enhanced MRI ranged from 56 to 83% [23,
31].
In this study, we compared MRI with administration
of the hepatobiliary agent MnDPDP with spiral CT for
the detection of hepatic colorectal metastases in a series
of patients who were candidates for surgical resection or
intraoperative radio-frequency thermal ablation and in
whom intraoperative US findings could be used as term
of reference. In a lesion-by-lesion analysis, MRI signifi-
cantly outperformed spiral CT and unenhanced MRI in
the detection of metastatic deposits. The overall sensitiv-
ity of MnDPDP-enhanced MRI reached 90% as opposed
to 71% for spiral CT and 72% of unenhanced MRI. The
difference in the detection rate between MnDPDP-
enhanced MRI and spiral CT was even more manifest
when only lesions ≤1 cm in diameter were considered: in
this group, MnDPDP-enhanced MRI showed a sensitivi-
ty of 83% as opposed to 38% of spiral CT and 51% of
unenhanced MRI.
Analysis of our data on a patient-by-patient basis con-
firmed the superiority of MnDPDP-enhanced MRI over
baseline MRI and spiral CT. While the extent of the he-
patic metastatic burden was underestimated or overesti-
mated in half of the patients by unenhanced MRI and
spiral CT, findings at MnDPDP-enhanced MRI were in
agreement with those at intraoperative US in 75% of the
cases. Nevertheless, either false-negative or, occasional-
ly, false-positives lesions occurred in the remaining 25%
of patients even with use of MnDPDP-enhanced MRI.
Our findings confirm, in a larger series of patients, the
results of a recent investigation, in which MRI with
MnDPDP correlated with findings of intraoperative US
in 70% of the patients [32]. Of interest, in our series as
well as in that report, all lesions undetected by
MnDPDP-enhanced MRI and discovered at the time of
surgery by intraoperative US did not exceed 1 cm in di-
ameter.
There were some limitations to our study. Firstly, as
for any multicenter trial, imaging examinations were per-
Table 4 Quality of lesion delineation in unenhanced MR images, MnDPDP-enhanced MR images, and spiral CT images
Absent Poor Moderate Excellent Not assessed
Spiral CT 1 (1.1) 6 (6.6) 46 (50.6) 38 (41.8) –
Unenhanced T1-weighted SE 2 (2.7) 23 (30.7) 42 (56) 8 (10.7) –
Unenhanced T1-weighted GRE – 19 (20.6) 47 (51.1) 25 (27.2) 1 (1.1)
Unenhanced T2-weighted FSE – 20 (23.0) 42 (48.3) 24 (27.6) 1 (1.2)
MnDPDP-enhanced T1-weighted SE 12 (13.5) 25 (28.1) 23 (25.8) 29 (32.6) –
MnDPDP-enhanced T1-weighted GRE – 3 (2.6) 17 (14.8) 94 (81.7) 1 (0.9)
Numbers in parentheses are percentages
Table 5 Diagnostic confidence in unenhanced MR images, MnDPDP-enhanced MR images, and spiral CT images
Not very Moderately Very confident Extremely Not 
confident confident confident assessed
Spiral CT 4 (3.1) 14 (10.9) 36 (28.1) 36 (28.1) 1 (1.1)
Unenhanced T1-weighted SE 20 (26.7) 24 (32.0) 17 (22.7) 14 (18.7) –
Unenhanced T1-weighted GRE 15 (16.3) 23 (25.0) 28 (30.4) 26 (28.3) –
Unenhanced T2-weighted FSE 14 (16.1) 28 (32.2) 23 (26.4) 22 (25.3) –
MnDPDP-enhanced T1-weighted SE 12 (13.5) 25 (28.1) 23 (25.8) 29 (32.6) –
MnDPDP-enhanced T1-weighted GRE 1 (0.9) 14 (12.2) 15 (13.0) 84 (73.0) 1 (0.9)
Numbers in parentheses are percentages
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formed with a variety of equipment; hence, local differ-
ences in the quality of CT and MRI scanners as well as in
the optimization of CT and MRI protocols might have af-
fected the comparative analysis of the results. Secondly,
our gold standard was provided by intraoperative US.
Since we had not the opportunity to examine pathologi-
cally the entire liver, we cannot exclude false-negative re-
sults in our standard of reference. Although this limita-
tion should not influence the results of comparative anal-
ysis of imaging modalities, absolute values of sensitivity
should be regarded with caution. Thirdly, contrary to pre-
vious series in which each MR pulse sequence was evalu-
ated separately, we compared—for the primary end point
of the study—two sets of MR images, including all the
precontrast and all the precontrast plus the postcontrast
sequences, respectively. We recognize that this approach
helps yield the best performance because visualization of
a questionable area on more than one type of MR image
can support the diagnosis of a focal lesion; however, this
study design (simultaneous evaluation of more than one
MR image obtained at the same anatomic level) simulates
the everyday practice of evaluation of cross-sectional im-
ages, and made the results of the study more clinically
applicable. Finally, specificity of imaging findings could
not be assessed since only patients with metastases were
included; hence, there were no “true negatives” on a pa-
tient-by-patient basis. On the other hand, lesion-by-lesion
analysis of specificity was impaired by the presence of
too few benign lesions in this series.
Conclusion
Our study showed that MnDPDP-enhanced MRI is supe-
rior to unenhanced MRI and contrast-enhanced spiral CT
for the detection of hepatic colorectal metastases. Be-
cause economic pressures favor the use of less expensive
imaging strategies, MnDPDP-enhanced MR imaging
should be reserved to be performed in patients in whom
metastases are of a pathologic type for which surgical re-
section or local tumor ablation have proved effective and
less expensive routine screening examinations have de-
picted only a number of metastases which makes surgery
or tumor ablation a feasible option.
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